Wealthfront Advisers
NVAX icon

Wealthfront Advisers’s Novavax NVAX Stock Holding History

Wealthfront Advisers’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,562
Closed -$50.7K – 878
2023
Q4 		$50.7K Buy
+10,562
New +$64.7K ﹤0.01% 857
2022
Q1 		– Sell
-14,623
Closed -$2.09M – 806
2021
Q4 		$2.09M Buy
14,623
+13,389
+1,085% +$2.3M 0.01% 374
2021
Q3 		$256K Buy
+1,234
New +$272K ﹤0.01% 648

Other funds holding NVAX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Wealthfront Advisers's NVAX Position: Q1 2024 in Review

Wealthfront Advisers sold out of Novavax (NVAX) in Q1 2024, closing a stake of 10,562 shares — an estimated $50.7K sold.

Wealthfront Advisers first reported a position in NVAX in Q3 2021 and held it in 3 quarters. The position peaked at $2.09M in Q4 2021. 201 funds tracked by Wall St. Rank hold NVAX as of Q1 2024.

  • Wealthfront Advisers reported no remaining Novavax position as of Q1 2024 after selling out during the quarter.
  • Wealthfront Advisers sold 10,562 Novavax shares in Q1 2024, an estimated $50.7K.
  • Wealthfront Advisers first reported a position in Novavax in Q3 2021 and held it in 3 quarters.
  • Wealthfront Advisers's Novavax position peaked at $2.09M in Q4 2021.
  • 201 funds tracked by Wall St. Rank held Novavax as of Q1 2024.

Based on Wealthfront Advisers's 13F filing for Q1 2024, filed 19 Apr 2024.